Diacerein is an anthraquinone derivative used for the symptomatic treatment of knee and hip osteoarthritis.
The mechanism of action of diacerein primarily consists in the inhibition of IL-1β production and activity1.
Obtained from Aloe Vera plants, diacerein is a symptomatic slow-acting drug for osteoarthritis (SYSADOA). It has clinically demonstrated efficacy to significantly relieve pain and improve joint function in patients with knee or hip osteoarthritis.2-6Patients benefit from being able to carry on with their everyday activities without the pain and functional restrictions often associated with osteoarthritis.
Find out more on your local website about our Diacerein containing medecine
Pavelka K, Bruyère O, Cooper C, Kanis JA, Leeb BF, et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging. 2016;33(2):75-85.
Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339-48.
Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994;37(4):529-36.
Lequesne M, Berdah L, Gérentes I. [Efficacy and tolerance of diacerhein in the treatment of gonarthrosis and coxarthrosis]. Rev Prat. 1998;48(Suppl 17):S31-5.
Zheng WJ, Tang FL, Li J, Zhang FC, Li ZG, Su Y, et al. Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients. Chin Med Sci J. 2006;21(2):75-80.
Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum. 2001;44(11):2539-47.
Video:
Boileau C, Tat SK, Pelletier JP, Cheng S, Martel-Pelletier J. Arthritis Res Ther. 2008;10(3):R71.
Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, et al. Arthritis Rheum. 2001;44(11):2539-47.
Dozin B, Malpeli M, Camardella L, Cancedda R, Pietrangelo A. Matrix Biol. 2002;21(5):449-59.
Ferreira Mendes A, Caramona MM, de Carvalho AP, Lopes MC. Pharmacol Toxicol. 2002;91(1):22-8.
Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Lancet. 2015;386(9991):376-87.
Jacques C, Gosset M, Berenbaum F, Gabay C. Vitam Horm. 2006;74:371-403.
Legendre F, Bogdanowicz P, Martin G, Domagala F, Leclercq S, Pujol JP, et al. Clin Exp Rheumatol. 2007;25(4):546-55.
Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P. Lymphokine Cytokine Res. 1991;10(1-2):15-21. Nicolas P, Tod M, Padoin C, Petitjean O. Clin Pharmacokinet. 1998;35(5):347-59.
Pavelka K, Bruyere O, Cooper C, Kanis JA, Leeb BF, Maheu E, et al. Drugs Aging. 2016;33(2):75-85.
Yaron M, Shirazi I, Yaron I. Osteoarthritis Cartilage. 1999;7(3):272-80
You are about to leave the TRB corporate website. This link will take you to a local TRB website. Medical practices and regulations can be different from one country to another.
As a result, the medical information provided in the site which you are going to visit may not be appropriate for product use in your country.
Argentina 
Asia-pacific 
Austria 
Brazil 
England 
Germany 
Hong Kong 
Malaysia 
Netherlands 
Poland 
Switzerland 
France 
